Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 15/20 | 0.50 |
| ▸ | JAK1 | P23458 | 15/20 | 0.50 |
| ▸ | TYK2 | P29597 | 15/20 | 0.50 |
| ▸ | JAK3 | P52333 | 15/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24771131 | 0.96 | JAK2 (0.52) | JAK2JAK1TYK2JAK3KMT2A | |
| SCHEMBL24771134 | 0.96 | JAK2 (0.52) | JAK2JAK1TYK2JAK3KMT2A | |
| SCHEMBL22904894 | 0.90 | MCL1 (0.43) | JAK2JAK1TYK2JAK3KMT2A | |
| SCHEMBL22909074 | 0.90 | JAK2 (0.51) | JAK2JAK1TYK2JAK3KMT2A | |
| SCHEMBL29443069 | 0.90 | MCL1 (0.43) | JAK2JAK1TYK2JAK3KMT2A | |
| SCHEMBL22908952 | 0.89 | JAK2 (0.50) | JAK2JAK1TYK2JAK3KMT2A | |
| SCHEMBL24772450 | 0.88 | KDM4E (0.51) | JAK2JAK1TYK2JAK3KMT2A | |
| SCHEMBL22908889 | 0.86 | JAK2 (0.48) | JAK2JAK1TYK2JAK3KMT2A | |
| SCHEMBL22908950 | 0.86 | JAK2 (0.48) | JAK2JAK1TYK2JAK3KMT2A | |
| SCHEMBL22908987 | 0.86 | JAK2 (0.48) | JAK2JAK1TYK2JAK3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114206882-B | Benzothiophene, thienopyridine and thienopyrimidine derivatives for modulating STING | CTXT私人有限公司 | 2024-11-12 | — | — | CN | disclosed |
| US-20220389032-A1 | BENZOTHIOPHENE, THIENOPYRIDINE AND THIENOPYRIMIDINE DERIVATIVES FOR THE MODULATION OF STING | CTXT PTY LTD. (AU) | 2022-12-08 | — | — | US | disclosed |
| EP-3999185-A1 | BENZOTHIOPHENE, THIENOPYRIDINE AND THIENOPYRIMIDINE DERIVATIVES FOR THE MODULATION OF STING | CTXT Pty Limited (AU) | 2022-05-25 | — | — | EP | disclosed |
| CN-114206882-A | Benzothiophene, thienopyridine, and thienopyrimidine derivatives for modulation of STING | CTXT私人有限公司 | 2022-03-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389032-A1 | BENZOTHIOPHENE, THIENOPYRIDINE AND THIENOPYRIMIDINE DERIVATIVES FOR THE MODULATION OF STING | STING1, CGAS, MAVS | JAK2 1293/4885JAK1 1245/4885TYK2 980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.